Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can walking keep cancer away? new study investigates

NCT ID NCT04589468

Prevention Sponsor: City of Hope Medical Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Aug 28, 2026 · Updated 4 times

Summary

This study explores whether aerobic exercise, like walking, can lower levels of ctDNA (a marker of cancer in the blood) and help prevent breast, prostate, or colorectal cancer from coming back. Researchers will test different amounts of weekly exercise (90 to 375 minutes) in 33 people who have already been treated for cancer. The goal is to find the safest and most effective exercise dose to test further.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
aerobic exercise (walking)
What this could lead to
If it works, this could point toward a simple, drug-free way to reduce the risk of cancer coming back after initial treatment.
What could go wrong
This is a very early, small study (33 participants) testing different exercise doses. It may not show a clear benefit, and results may not apply to all cancer types or stages.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 51 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2026

An estimate. Start dates often move.

Expected to finish

Feb 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Postsurgical diagnosis of patients with primary solid tumors at high-risk of relapse as defined by one of the following: ° High-risk primary solid tumor (e.g., colorectal, ovarian, non-small cell lung cancer) (colorectal cancer only for Phase 1a) * Stage 3 or * ctDNA positive ° High-risk breast cancer * Residual invasive disease in the breast or the lymph nodes following completion of neoadjuvant chemotherapy (NACT), * Estrogen receptor (ER), and/or progesterone receptor (PR) positive and HER2 negative, * CPS-EG score ≥ 3, * CPS-EG score ≥2 w ith ypN+, or * Recurrence score ≥ 25 * No evidence of disease * Age ≥ 18 * Interval of ≥ 1 month but ≤ 2 years following completion of all definitive adjuvant therapy * Non-exercising (i.e., \< 30 minutes of moderate and \< 20 mins of vigorous exercise/wk), as assessed by remote activity and heart rate tracking for a 7-day period prior to study entry) ° If ≥ 30 minutes but less than 45 minutes of moderate exercise/week, or if ≥ 20 minutes but less than 30 minutes of vigorous exercise/week, patients may be eligible, at the discretion of the PI. * Cleared for exercise participation as per screening clearance via PAR-Q+ * Willingness to comply with all study-related procedures Exclusion Criteria: * Enrollment onto any other interventional investigational study except interventions determined by the PI not to confound study outcomes * Any other current diagnosis of invasive cancer of any kind * Distant metastatic malignancy of any kind * Any other condition or intercurrent illness that, in the opinion of the investigator, makes the subject a poor candidate for study participation

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm colorectal cancer colorectal neoplasm Motor Activity prostate cancer prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Breast cancer Colorectal cancer Prostate cancer Stage I breast cancer Stage I colorectal cancer Stage I prostate cancer Stage II breast cancer Stage II colorectal cancer Stage II prostate cancer Stage III breast cancer Stage III colorectal cancer Stage III prostate cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • City of Hope Medical Center

    RECRUITING

    Durate, California, 91010, United States

  • Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)

    ACTIVE_NOT_RECRUITING

    Basking Ridge, New Jersey, 07920, United States

  • Memorial Sloan Kettering Bergen (Limited Protocol Activities)

    ACTIVE_NOT_RECRUITING

    Montvale, New Jersey, 07645, United States

  • Memorial Sloan Kettering Cancer Center

    ACTIVE_NOT_RECRUITING

    New York, New York, 10065, United States

  • Memorial Sloan Kettering Commack (Limited Protocol Activities)

    ACTIVE_NOT_RECRUITING

    Commack, New York, 11725, United States

  • Memorial Sloan Kettering Monmouth (Limited Protocol Activities)

    ACTIVE_NOT_RECRUITING

    Middletown, New Jersey, 07748, United States

  • Memorial Sloan Kettering Nassau (Limited Protocol Activities)

    ACTIVE_NOT_RECRUITING

    Uniondale, New York, 11553, United States

  • Memorial Sloan Kettering Westchester (Limited Protocol Activities)

    ACTIVE_NOT_RECRUITING

    Harrison, New York, 10604, United States

  • Natera, Inc. (Data or Specimen Analysis Only)

    NOT_YET_RECRUITING

    San Carlos, California, 94070, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.